利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

97 条记录 (耗时 0.054 秒)

    FcgammaRIIB-Specific Antibodies and Methods of Use Thereof
    1.
    发明申请
    FcgammaRIIB-Specific Antibodies and Methods of Use Thereof 审中-公开
    FcgammaRIIB特异性抗体及其使用方法

    公开(公告)号：US20150023964A1

    公开(公告)日：2015-01-22

    申请号：US14331360

    申请日：2014-07-15

    申请人： Leslie S. Johnson ,  Ling Huang ,  Robyn Gerena

    发明人： Leslie S. Johnson ,  Ling Huang ,  Robyn Gerena

    IPC分类号： C07K16/28 ,  A61K45/06 ,  A61K39/395

    CPC分类号： C07K16/283 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K2317/34 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/92

    摘要： The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, with greater affinity than the antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA. The present invention also provides the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, as a single agent therapy for the treatment, prevention, management, or amelioration of a cancer, preferably a B-cell malignancy, particularly, B-cell chronic lymphocytic leukemia or non-Hodgkin's lymphoma, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention.

    摘要翻译： 本发明涉及以比抗体或其片段更大的亲和力结合FcγRIIA，特别是人FcγRIIA的FcγRIIB特别是人FcγRIIB特异性结合的抗体或其片段。 本发明还提供抗FcγRIIB抗体或其抗原结合片段作为治疗，预防，治疗或改善癌症，优选B细胞恶性肿瘤，特别是B细胞恶性肿瘤的单一药物治疗的用途 细胞性慢性淋巴细胞白血病或非霍奇金淋巴瘤，自身免疫性疾病，炎症性疾病，IgE介导的过敏性疾病或其一种或多种症状。 本发明提供了通过施用本发明的抗体来增强治疗性抗体的效应功能来增强治疗性抗体的治疗效果的方法。 本发明还提供了通过施用本发明的抗体来增强疫苗组合物的功效的方法。

    FcγRIIB—specific antibodies and methods of use thereof
    2.
    发明授权
    FcγRIIB—specific antibodies and methods of use thereof 有权
    FcγRIIB特异性抗体及其使用方法

    公开(公告)号：US08785599B2

    公开(公告)日：2014-07-22

    申请号：US11768852

    申请日：2007-06-26

    申请人： Leslie S. Johnson ,  Ling Huang ,  Robyn Gerena

    发明人： Leslie S. Johnson ,  Ling Huang ,  Robyn Gerena

    IPC分类号： C07K16/00 ,  C12P21/08 ,  A61K39/395 ,  A61K39/40 ,  C07K1/00

    CPC分类号： C07K16/283 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K2317/34 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/92

    摘要： The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, with greater affinity than the antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA. The present invention also provides the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, as a single agent therapy for the treatment, prevention, management, or amelioration of a cancer, preferably a B-cell malignancy, particularly, B-cell chronic lymphocytic leukemia or non-Hodgkin's lymphoma, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention.

    摘要翻译： 本发明涉及以比抗体或其片段更大的亲和力结合FcγRIIA，特别是人FcγRIIA的FcγRIIB特别是人FcγRIIB特异性结合的抗体或其片段。 本发明还提供抗FcγRIIB抗体或其抗原结合片段作为治疗，预防，治疗或改善癌症，优选B细胞恶性肿瘤，特别是B细胞恶性肿瘤的单一药物治疗的用途 细胞性慢性淋巴细胞白血病或非霍奇金淋巴瘤，自身免疫性疾病，炎症性疾病，IgE介导的过敏性疾病或其一种或多种症状。 本发明提供了通过施用本发明的抗体来增强治疗性抗体的效应功能来增强治疗性抗体的治疗效果的方法。 本发明还提供了通过施用本发明的抗体来增强疫苗组合物的功效的方法。

    Fc.gamma.RIIB-Specific Antibodies and Methods of Use Thereof
    3.
    发明申请
    Fc.gamma.RIIB-Specific Antibodies and Methods of Use Thereof 有权
    Fc.gamma.RIIB特异性抗体及其使用方法

    公开(公告)号：US20080044429A1

    公开(公告)日：2008-02-21

    申请号：US11768852

    申请日：2007-06-26

    申请人： Leslie Johnson ,  Ling Huang ,  Robyn Gerena

    发明人： Leslie Johnson ,  Ling Huang ,  Robyn Gerena

    IPC分类号： A61K39/395 ,  A61P35/00 ,  C07H21/00 ,  C07K16/00 ,  C07K16/30 ,  C07K7/06 ,  C07K7/08 ,  C12N1/00 ,  C12N15/63 ,  C12P21/02

    CPC分类号： C07K16/283 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K2317/34 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/92

    摘要： The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, with greater affinity than said antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA. The present invention also provides the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, as a single agent therapy for the treatment, prevention, management, or amelioration of a cancer, preferably a B-cell malignancy, particularly, B-cell chronic lymphocytic leukemia or non-Hodgkin's lymphoma, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention.

    摘要翻译： 本发明涉及以比所述抗体或其片段更大的亲和力结合FcγRIIA，特别是人FcγRIIA的FcγRIIB特别是人FcγRIIB特异性结合的抗体或其片段。 本发明还提供抗FcγRIIB抗体或其抗原结合片段作为单一药物治疗用于治疗，预防，治疗或改善癌症，优选B细胞恶性肿瘤，特别是B细胞 细胞性慢性淋巴细胞白血病或非霍奇金淋巴瘤，自身免疫性疾病，炎症性疾病，IgE介导的过敏性疾病或其一种或多种症状。 本发明提供了通过施用本发明的抗体来增强治疗性抗体的效应功能来增强治疗性抗体的治疗效果的方法。 本发明还提供了通过施用本发明的抗体来增强疫苗组合物的功效的方法。

    Humanized FcγRIIB-specific antibodies and methods of use thereof
    5.
    发明授权
    Humanized FcγRIIB-specific antibodies and methods of use thereof 有权
    人源化FcγRIIB特异性抗体及其使用方法

    公开(公告)号：US08216579B2

    公开(公告)日：2012-07-10

    申请号：US12785117

    申请日：2010-05-21

    申请人： Leslie S. Johnson ,  Ling Huang

    发明人： Leslie S. Johnson ,  Ling Huang

    IPC分类号： A61K39/395

    CPC分类号： A61K39/39 ,  A61K2039/505 ,  A61K2039/55516 ,  C07K16/283 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/52 ,  G01N33/564 ,  G01N33/6893 ,  G01N2800/24

    摘要： The present invention relates to humanized FcγRIIB antibodies, fragments, and variants thereof that bind human FcγRIIB with a greater affinity than said antibody binds FcγRIIA. The invention encompasses the use of the humanized antibodies of the invention for the treatment of any disease related to loss of balance of Fc receptor mediated signaling, such as cancer, autoimmune and inflammatory disease. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the humanized antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing the efficacy of a vaccine composition by administering the humanized antibodies of the invention. The invention encompasses methods for treating an autoimmune disease and methods for elimination of cancer cells that express FcγRIIB.

    摘要翻译： 本发明涉及以比所述抗体结合FcγRIIA更大的亲和力结合人FcγRIIB的人源化FcγRIIB抗体，其片段和变体。 本发明包括本发明的人源化抗体用于治疗与Fc受体介导的信号传导的平衡丧失有关的任何疾病（例如癌症，自身免疫性和炎症性疾病）的用途。 本发明提供了通过施用本发明的人源化抗体来增强治疗性抗体的治疗效果以增强治疗性抗体的效应子功能的方法。 本发明还提供了通过施用本发明的人源化抗体来增强疫苗组合物的功效的方法。 本发明包括治疗自身免疫性疾病的方法和用于消除表达FcγRIIB的癌细胞的方法。

    Covalent diabodies and uses thereof
    8.
    发明授权
    Covalent diabodies and uses thereof 有权
    共价双抗体及其用途

    公开(公告)号：US09296816B2

    公开(公告)日：2016-03-29

    申请号：US11409339

    申请日：2006-04-17

    申请人： Leslie S. Johnson ,  Ling Huang

    发明人： Leslie S. Johnson ,  Ling Huang

    IPC分类号： C07K16/28 ,  A61K39/00

    CPC分类号： C07K16/283 ,  A61K2039/505 ,  C07K16/08 ,  C07K16/12 ,  C07K16/30 ,  C07K16/44 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/52 ,  C07K2317/53 ,  C07K2317/622 ,  C07K2317/626

    摘要： The present invention is directed to diabody molecules and uses thereof in the treatment of a variety of diseases and disorders, including immunological disorders, infectious disease, intoxication and cancers. The diabody molecules of the invention comprise two polypeptide chains that associate to form at least two epitope binding sites, which may recognize the same or different epitopes on the same or differing antigens. Additionally, the antigens may be from the same or different molecules. The individual polypeptide chains of the diabody molecule may be covalently bound through non-peptide bond covalent bonds, such as, but not limited to, disulfide bonding of cysteine residues located within each polypeptide chain. In particular embodiments, the diabody molecules of the present invention further comprise an Fc region, which allows antibody-like functionality to engineered into the molecule.

    摘要翻译： 本发明涉及双抗体分子及其在治疗各种疾病和病症（包括免疫学疾病，感染性疾病，中毒和癌症）中的用途。 本发明的双抗体分子包含两个缔合以形成至少两个表位结合位点的多肽链，其可识别相同或不同抗原上相同或不同的表位。 另外，抗原可以来自相同或不同的分子。 双抗体分子的单个多肽链可以通过非肽键共价键共价结合，例如但不限于位于每个多肽链内的半胱氨酸残基的二硫键。 在具体实施方案中，本发明的双抗体分子还包含Fc区，其允许抗体样功能被改造成分子。

    Covalent diabodies and uses thereof
    9.
    发明授权
    Covalent diabodies and uses thereof 有权

    公开(公告)号：US09284375B2

    公开(公告)日：2016-03-15

    申请号：US12641095

    申请日：2009-12-17

    申请人： Leslie S. Johnson ,  Ling Huang

    发明人： Leslie S. Johnson ,  Ling Huang

    IPC分类号： C07K16/00 ,  C07K16/28

    CPC分类号： C07K16/283 ,  C07K2317/34 ,  C07K2317/52 ,  C07K2317/626 ,  C07K2317/73

    摘要： The present invention is directed to diabody molecules and uses thereof in the treatment of a variety of diseases and disorders, including immunological disorders, infectious disease, intoxication and cancers. The diabody molecules of the invention comprise two polypeptide chains that associate to form at least two epitope binding sites, which may recognize the same or different epitopes on the same or differing antigens. Additionally, the antigens may be from the same or different molecules. The individual polypeptide chains of the diabody molecule may be covalently bound through non-peptide bond covalent bonds, such as, but not limited to, disulfide bonding of cysteine residues located within each polypeptide chain. In particular embodiments, the diabody molecules of the present invention further comprise an Fc region, which allows antibody-like functionality to engineered into the molecule.